Literature DB >> 25716300

Neurodegenerative diseases and therapeutic strategies using iron chelators.

Roberta J Ward1, David T Dexter2, Robert R Crichton3.   

Abstract

This review will summarise the current state of our knowledge concerning the involvement of iron in various neurological diseases and the potential of therapy with iron chelators to retard the progression of the disease. We first discuss briefly the role of metal ions in brain function before outlining the way by which transition metal ions, such as iron and copper, can initiate neurodegeneration through the generation of reactive oxygen and nitrogen species. This results in protein misfolding, amyloid production and formation of insoluble protein aggregates which are contained within inclusion bodies. This will activate microglia leading to neuroinflammation. Neuroinflammation plays an important role in the progression of the neurodegenerative diseases, with activated microglia releasing pro-inflammatory cytokines leading to cellular cell loss. The evidence for metal involvement in Parkinson's and Alzheimer's disease as well as Friedreich's ataxia and multiple sclerosis will be presented. Preliminary results from trials of iron chelation therapy in these neurodegenerative diseases will be reviewed.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Chelation; Iron; Neurodegenerative diseases

Mesh:

Substances:

Year:  2015        PMID: 25716300     DOI: 10.1016/j.jtemb.2014.12.012

Source DB:  PubMed          Journal:  J Trace Elem Med Biol        ISSN: 0946-672X            Impact factor:   3.849


  32 in total

1.  Mitoferrin-1 is required for brain energy metabolism and hippocampus-dependent memory.

Authors:  Lisa Baldauf; Thomas Endres; Johannes Scholz; Elmar Kirches; Diane M Ward; Volkmar Lessmann; Katrin Borucki; Christian Mawrin
Journal:  Neurosci Lett       Date:  2019-09-26       Impact factor: 3.046

2.  Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy.

Authors:  Qingchun Zhang; Shufan Feng; Yulian Zhao; Bo Jin; Rufang Peng
Journal:  J Biol Inorg Chem       Date:  2021-05-08       Impact factor: 3.358

Review 3.  Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care.

Authors:  Yi Wang; Pascal Spincemaille; Zhe Liu; Alexey Dimov; Kofi Deh; Jianqi Li; Yan Zhang; Yihao Yao; Kelly M Gillen; Alan H Wilman; Ajay Gupta; Apostolos John Tsiouris; Ilhami Kovanlikaya; Gloria Chia-Yi Chiang; Jonathan W Weinsaft; Lawrence Tanenbaum; Weiwei Chen; Wenzhen Zhu; Shixin Chang; Min Lou; Brian H Kopell; Michael G Kaplitt; David Devos; Toshinori Hirai; Xuemei Huang; Yukunori Korogi; Alexander Shtilbans; Geon-Ho Jahng; Daniel Pelletier; Susan A Gauthier; David Pitt; Ashley I Bush; Gary M Brittenham; Martin R Prince
Journal:  J Magn Reson Imaging       Date:  2017-03-10       Impact factor: 4.813

4.  Regionally progressive accumulation of iron in Parkinson's disease as measured by quantitative susceptibility mapping.

Authors:  Xiaojun Guan; Min Xuan; Quanquan Gu; Peiyu Huang; Chunlei Liu; Nian Wang; Xiaojun Xu; Wei Luo; Minming Zhang
Journal:  NMR Biomed       Date:  2016-02-08       Impact factor: 4.044

Review 5.  Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation.

Authors:  Stefan W Ryter; Augustine M K Choi
Journal:  Transl Res       Date:  2015-06-23       Impact factor: 7.012

Review 6.  Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease.

Authors:  Xiaojun Guan; Xiaojun Xu; Minming Zhang
Journal:  Neurosci Bull       Date:  2017-05-17       Impact factor: 5.203

Review 7.  Appraising the Role of Iron in Brain Aging and Cognition: Promises and Limitations of MRI Methods.

Authors:  Ana M Daugherty; Naftali Raz
Journal:  Neuropsychol Rev       Date:  2015-08-07       Impact factor: 7.444

Review 8.  Pharmacokinetics, pharmacodynamics and toxicology of theranostic nanoparticles.

Authors:  Homan Kang; Shrutika Mintri; Archita Venugopal Menon; Hea Yeon Lee; Hak Soo Choi; Jonghan Kim
Journal:  Nanoscale       Date:  2015-11-03       Impact factor: 7.790

Review 9.  Ethnic Differences in Iron Status.

Authors:  Wanhui Kang; Alexa Barad; Andrew G Clark; Yiqin Wang; Xu Lin; Zhenglong Gu; Kimberly O O'Brien
Journal:  Adv Nutr       Date:  2021-10-01       Impact factor: 8.701

10.  Conjugates of desferrioxamine and aromatic amines improve markers of iron-dependent neurotoxicity.

Authors:  Rodrigo R V Carvalho; Tanara V Peres; Cleber W Liria; M Teresa Machini; Michael Aschner; Breno P Espósito
Journal:  Biometals       Date:  2021-01-03       Impact factor: 2.949

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.